The California-based biotech continued its rocket-like ascent in 2015–just two years ago it ranked No. 250 on the 500–due to booming sales of its breakthrough Hepatitis C medications. Those drugs–Sovaldi and Harvoni–which cost a fortune, but also cure a chronic, devastating disease, sparked a national debate on drug pricing. They also drove Gilead’s bottom and top lines in 2015–revenues and profits jumped 31% and 50%, respectively. John Milligan, Gilead’s new CEO faces rockier road in 2016: the competition is stiffer and IP challenges and pricing pressures loom.
News about Gilead Sciences
And why the world needs even more affordable drugs.
Pfizer has agreed to pay a little more than $80 per share for Medivation, a source said.
Brand reputation isn't necessarily tied to cash giving, however.
If you want to invest like Donald Trump.
It's one of 85 that have been deemed just too expensive.